Evidence map›Paper›PMID 36588407›Full record

ArticleAmerican journal of hematology2023

Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.

Charles Dumontet, Delphine Demangel, Perrine Galia, Lionel Karlin, Laurent Roche, Mathieu Fauvernier, Camille Golfier, Marie-Charlotte Laude, Xavier Leleu, Philippe Rodon and 29 more

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
In one paragraph

Article in American journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02853214 (Identification of Genetic Factors Predisposing to Dysglobulinemia), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02853214 nacompletednot on this map

Identification of Genetic Factors Predisposing to Dysglobulinemia

TypeinterventionalSponsorHospices Civils de LyonRan2008 to 2023Enrolled1,868ConditionsDysglobulinemiaArmsGenetic analysis of peripheral blood samples
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Nanoimmunotherapy: the smart trooper for cancer therapy.Exploration of targeted anti-tumor therapy · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 4 countries.

Charles DumontetHospices Civils de Lyon, Lyon, France.ORCID 0000-0003-1875-134X
Delphine DemangelHospices Civils de Lyon, Lyon, France.ORCID 0000-0001-6550-2827
Perrine GaliaHospices Civils de Lyon, Lyon, France.
Lionel KarlinHospices Civils de Lyon, Lyon, France.
Laurent RocheHospices Civils de Lyon, Lyon, France.
Mathieu FauvernierHospices Civils de Lyon, Lyon, France.
Camille GolfierHospices Civils de Lyon, Lyon, France.
Marie-Charlotte LaudeHospices Civils de Lyon, Lyon, France.ORCID 0000-0001-9967-706X
Xavier LeleuHematology Department, CHU Poitiers, Poitiers, France.
Philippe RodonHematology Department, CH Périgueux, Périgueux, France.
Murielle RousselIUC-Oncopôle, Toulouse, France.
Isabelle AzaïsHematology Department, CHU Poitiers, Poitiers, France.
Chantal DoyenUCL Mont-Godinne, Louvain, Belgium.
Borhane SlamaClinical Hematology Department, CH Avignon, Avignon, France.
Salomon ManierHematology Department, CHRU, Lille, France.
Olivier DecauxHematology Department, CHU Rennes, Inserm UMR1236, Rennes, France.
Maroulio PertesiGenetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Marie BeaumontHematology Department, CHU Dunkerque, Dunkerque, France.
Denis CaillotClinical Hematology Department, Hôpital F. Mitterrand, CHU Dijon, Dijon, France.
Eileen M BoylePerlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
Manuel CliquennoisHospitals Organization of Catholic Institute, Lille, France.ORCID 0000-0002-4544-7661
Pascale Cony-MakhoulCH Annecy Genevois, Pringy, France.
Anne-Violaine DonckerPrivate Hospital Sévigné, Cesson-Sévigné, France.
Véronique DorvauxClinical Hematology Department, CHR Metz-Thionville, Metz-Thionville, France.
Marie Odile PetillonIntergroupe Francophone du Myélome, France.
Jean FontanHematology Department, CHU Besançon, Besançon, France.
Bénédicte HivertHospitals Organization of Catholic Institute, Lille, France.
Isabelle LeducHematology Department, CH d'Abbeville, Abbeville, France.
Cécile LeyronnasDaniel Hollard Institute-GHM-Grenoble, Grenoble, France.
Margaret MacroHematology Department, CHU Caen, Caen, France.
Michel MaigreInternal Medicine Department, CH Chartres, Chartres, France.
Clara MarietteHematology Department, CHU Grenoble, Grenoble, France.
Philippe MineurClinical Hematology Department, Grand Hôpital de Charleroi, Charleroi, Belgium.
Sophie RigaudeauHematology Department, CH Versailles, Versailles, France.
Bruno RoyerClinical Hematology and Cell Therapy Department, Amiens, France.
Laure VincentClinical Hematology Department, CHU Montpellier, France.
James MckayGenetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Emeline PerrialCRCL, UMR INSERM 1052/CNRS 5286/University of Lyon-France, Lyon, France.
Laurent GarderetHU PITIE SALPETRIERE APHP, Paris, France.ORCID 0000-0002-6138-8112
Hospices Civils de Lyon · FRCentre Hospitalier Universitaire de Poitiers · FRGroupe Hospitalier de l'Institut Catholique de Lille · FRInserm · FRUniversité Claude Bernard Lyon 1 · FRCentre Hospitalier Annecy Genevois · FRCentre Hospitalier d'Albi · FRCentre Hospitalier Régional de Metz-Thionville · FRCentre Hospitalier Universitaire Amiens-Picardie · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire de Caen Normandie · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Montpellier · FRCentre international de recherche sur le cancer · FRGrand Charleroi Hospital · BEInstitut universitaire du cancer de Toulouse Oncopole · FRIntergroupe Francophone du Myélome · FRLaboratoire Informatique d'Avignon · FRLes Hôpitaux de Chartres · FRLund University · SE

Funding

World Health Organization 001
6 · The paper itself

Abstract

Familial forms of monoclonal gammopathy, defined as multiple myeloma (MM) or Monoclonal Gammopathy of Undetermined Significance (MGUS), are relatively infrequent and most series reported in the literature describe a limited number of families. MM rarely occurs in a familial context. MGUS is observed much more commonly, which can in some cases evolve toward full-blown MM. Although recurrent cytogenetic abnormalities have been described in tumor cells of sporadic cases of MM, the pathogenesis of familial MM remains largely unexplained. In order to identify genetic factors predisposing to familial monoclonal gammopathy, the Intergroupe Francophone du Myélome identified 318 families with at least two confirmed cases of monoclonal gammopathy. There were 169 families with parent/child pairs and 164 families with cases in at least two siblings, compatible with an autosomal transmission. These familial cases were compared with sporadic cases who were matched for age at diagnosis, sex and immunoglobulin isotype, with 10 sporadic cases for each familial case. The gender distribution, age and immunoglobulin subtypes of familial cases were unremarkable in comparison to sporadic cases. With a median follow-up of 7.4 years after diagnosis, the percentage of MGUS cases having evolved to MM was 3%. The median overall survival of the 148 familial MM cases was longer than that of matched sporadic cases, with projected values of 7.6 and 16.1 years in patients older and younger than 65 years, respectively. These data suggest that familial cases of monoclonal gammopathy are similar to sporadic cases in terms of clinical presentation and carry a better prognosis.

Indexed as

Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaParaproteinemiasChildChromosome AberrationsHumansPrognosis

Identifiers

PMID36588407
PMCPMC10107808
OpenAlexW4313424448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.